Drug Profile

Dofetilide intravenous - Hyloris Pharmaceuticals

Alternative Names: Dofetilide IV; HY-CVS-033

Latest Information Update: 20 Mar 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Hyloris Pharmaceuticals
Class Antiarrhythmics; Class III antiarrhythmics; Phenethylamines; Small molecules; Sulfonamides
Mechanism of Action Potassium channel antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes - Atrial fibrillation

Highest Development Phases

Clinical Phase Unknown Atrial fibrillation

Most Recent Events

14 Mar 2024 Hyloris Pharmaceuticals files for patent protection for Dofetilide IV in USA prior to March 2024
14 Mar 2024 Clinical trials in Atrial fibrillation (IV) prior to March 2024
14 Mar 2024 Hyloris Pharmaceuticals announces intention to submit NDA to US FDA for Atrial fibrillation

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com